Neuroprotection is defined as the ability for a therapy to prevent neuronal cell death by intervening in and inhibiting the pathogenetic cascade that results in cell dysfunction and eventual death. Neuroprotection is involvement capable to affect the etiology or the pathogenesis of the neurodegenerative diseases. They delay the onset or the development of neurodegenerative diseases. Neuroprotective products are medications that protect the brain neurons from deterioration and injury. These products are used in the cure of several central nervous system complications such as Alzheimer's disease, Parkinson's disease and traumatic brain injuries among others. Neuroprotective agents in clinical pipelines comprise small-molecule drugs, gene and cell therapies, therapeutic monoclonal antibodies and other agents.
Neuroprotection refers to the use of therapies that reduce brain injury during acute stroke, through actions on the brain rather than by improving blood flow. Over 1,000 neuroprotective agents have been studies in preclinical stroke research, many with promising results. Nearly 200 neuroprotective clinical trials have been completed but very few have achieved success. As a result, neuroprotection research has been perceived that everything works in animal but nothing works in people. In a rat stoke model, even single whisker stimulation could induce complete protection of rat cortex.
The global neuroprotection market is segmented on the basis of product and application. Based on product, the neuroprotection market has been segmented into free radical trapping agents (antioxidants), apoptosis inhibitors, anti-inflammatory agents, glutamate antagonists (anti-excitotoxic agents), metal ion chelators and others. The application segment is classified as treatment and prevention.
Source: The Insight Partners